PMN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Stats
Today's Volume	1 029.00
Average Volume	17 814.00
Market Cap	37.54M
EPS	$0 ( 2024-04-03 )
Next earnings date	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.850
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-02	Warma Neil K	Buy	200 000	Option (right to buy)
2023-12-04	Sclar Jeremy M.	Buy	150 000	Series 2 Preferred Shares, no par value
2022-10-11	Sclar Jeremy M.	Buy	26 217	Warrants to Purchase Common Shares, no par value
2023-12-04	Sclar Jeremy M.	Sell	150 000	Series 1 Preferred Shares, no par value
2023-12-25	Title 19 Promis	Sell	0	Common Shares, no par value

INSIDER POWER
-43.14
Last 83 transactions
Buy: 847 135 \| Sell: 2 093 488

ProMIS Neurosciences, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ProMIS Neurosciences, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.070

FY	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.070

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.700

Financial Reports:

No articles found.

ProMIS Neurosciences,

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.